Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma by unknown




Xuefeng Sun1†, Ruie Feng2†, Ye Zhang3†, Juhong Shi1 and Kai-Feng Xu1*
Abstract
Background: Lymphangioleiomyomatosis (LAM) and angiomyolipoma are two different, but related rare diseases.
To the best of our knowledge, pulmonary LAM and pulmonary angiomyolipoma have not previously been
observed in the same patient.
Case presentation: A 38-year-old woman presented with a dry cough and left flank pain. She had a right nephrectomy
for renal angiomyolipoma 17 years ago. A magnetic resonance imaging scan demonstrated a round mass in the left
kidney. A chest computed tomography scan demonstrated scattered small thin-walled cysts and multifocal round
nodules in both lungs. A lung biopsy via video-assisted thoracoscopic surgery revealed that the cysts and nodules
were manifestations of LAM and angiomyolipomas, respectively. After sirolimus therapy, the renal angiomyolipoma
and metastasized pulmonary angiomyolipomas shrank, but pulmonary cysts were unchanged.
Conclusions: LAM and angiomyolipoma are significantly associated, and may coexist in the lungs in rare cases.
Sirolimus is effective for both renal angiomyolipoma and metastasized pulmonary angiomyolipomas.
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Background
Lymphangioleiomyomatosis (LAM) is a rare, progressive
disease that typically results in cystic lung destruction and
predominantly affects women [1]. Angiomyolipoma is a
mesenchymal tumor and is the most common benign
tumor of the kidney. LAM and angiomyolipoma are differ-
ent, but substantially related conditions. Both are perivascu-
lar epithelial cell tumors and can arise from a common
source [2]. Renal angiomyolipoma is present in almost all
cases of tuberous sclerosis complex (TSC)-LAM and about
half of cases of sporadic LAM. However, to our knowledge,
pulmonary LAM and pulmonary angiomyolipoma have not
previously been observed simultaneously in the same
patient. Here we present the first case of coexisting pul-
monary LAM and pulmonary angiomyolipomas.
Case presentation
A 38-year-old woman presented with a dry cough and
left flank pain. Her medical history revealed a right
nephrectomy for renal tumor at the age of 21, but she
recovered from surgery without complications.
During physical examination, the patient had normal
vital signs, with a temperature of 36 °C, pulse of 80
beats/min, BP of 135/80 mmHg, respiratory rate of 18
breaths/min, and oxygen saturation of 98 % on ambient
air. She was conscious, with normal cognition. Physical
examinations were unremarkable, except for a surgical
cicatrix at the right lumber region. Both lungs were clear
to auscultation. The abdominal examination was normal,
and no percussion tenderness in the region of the kidney
was noted.
Complete blood count, urinalysis, renal and hepatic
functions were all in normal ranges. Serum VEGF-D was
615 ug/mL (<800 pg/mL). A chest computed tomog-
raphy (CT) scan demonstrated scattered small thin-
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walled cysts and 15 round nodules ranging in size from
5 mm to 24 mm in both lungs (Fig. 1a, b). Pulmonary
function tests revealed normal ventilation, lung volume
and diffusion capacity (FEV1 3.15 L/106.2 %, FEV1/FVC
77.6 %, TLC 112.9 %, and DLCO 91.9 %). Abdominal
magnetic resonance imaging scan and CT scan demon-
strated a round mass with a diameter of 4 cm on the
upper pole of the left kidney (Fig. 2a, b). Histopatho-
logical review of the tumor in the right kidney, resected
17 years ago, revealed it to be an angiomyolipoma.
Video-assisted thoracoscopic surgery was undertaken,
during which cysts and yellowish nodules were seen on
the surface of the lung (Fig. 3). Histopathologic analysis
of the lung specimen revealed that the cysts coincided
with LAM, while the nodules were angiomyolipomas,
consistent with that in the right kidney (Fig. 4).
Germinal TSC gene mutation was not detected in this
patient; therefore, the pulmonary LAM was considered to
be sporadic. Angiomyolipomas in the lungs and the left
kidney were predicted to have metastasized from the
resected right kidney. After the patient was prescribed
2 mg/d sirolimus, the cough and left flank pain were grad-
ually relieved. A CT scan 8 months later revealed that the
mass in the left kidney and some pulmonary nodules had
shrunk, but the cysts in both lungs were unchanged
(Figs. 1c and 2c).
Discussion
Pulmonary LAM is a rare lung disease that mainly affects
young women of childbearing age [3]. Pathologically,
LAM is characterized by the appearance of interstitial col-
lections of atypical smooth muscle cells and cyst forma-
tion in the lungs. LAM can be sporadic or associated with
TSC. Diffuse, small, symmetrical, thin-walled cysts are
characteristic hallmarks of LAM on chest CTs, as was
seen in this patient. Occasionally, multifocal micronodular
pneumocyte hyperplasia (MMPH) is seen in patients with
TSC or LAM on chest CT as random small pulmonary
nodules with ground-glass opacity, ranging in size from
1 mm to 1 cm [4, 5]. MMPH nodules are composed of
Fig. 1 a Chest computed tomography scan shows scattered thin-walled cysts (arrowheads) and round nodules (arrows) in the lungs. The largest
nodule (2.4 cm in diameter) was located in left upper lobe (white arrow). b The pulmonary nodule (white arrow) appears heterogeneous with
fatty components on the mediastinal window. c A repeat CT 8 months after sirolimus therapy reveals that the diameter of the largest nodule
(white arrow) has shrunk to 1.4 cm in diameter. A surgical scar (black arrow) is seen in the right upper lobe
Fig. 2 a An abdominal magnetic resonance imaging scan and b an abdominal CT scan showing a round heterogeneous mass of 4 cm in
diameter (arrow) on the upper pole of the left kidney. c Eight months after sirolimus therapy, the CT reveals that the mass has shrunk to 2.1 cm
in diameter
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thickened fibrotic alveolar septa lined by pleomorphic type
II pneumocytes. In our case, pulmonary nodules were ini-
tially thought to be an unusual manifestation of MMPH.
However, these nodules were consolidated and much lar-
ger than those described in the literature, which motivated
the decision to perform a biopsy.
Angiomyolipoma is a rare mesenchymal tumor com-
posed of adipose tissue, smooth muscle cells and thick-
walled vessels. It is the most common benign tumor of
the kidney. Both LAM and angiomyolipoma belong to a
family of tumors collectively termed neoplasms with peri-
vascular epithelioid differentiation, which are now referred
to as perivascular epithelial cell tumors (PEComas) [2].
HMB-45 and melan-A are present in angiomyolipoma,
differentiating it from other primary and secondary
mesenchymal or primary epithelial tumors [6]. In our
case, HMB-45 and melan-A were both expressed in
both renal and pulmonary tumors, confirming the diag-
nosis of angiomyolipoma. Most angiomyolipomas occur
in the kidney; in rare cases, extrarenal angiomyolipoma
may arise from the liver, mediastinum, uterus, sperm-
atic cord, retroperitoneum, spleen, skin and lung [7].
Renal angiomyolipomas may occur in association with
TSC, pulmonary LAM or occur as a sporadic finding.
Fig. 3 A yellowish nodule (arrow) and two cysts (arrowheads) are seen on the surface of the lung during video-assisted thoracoscopic surgery
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TSC has been estimated to be present in approximately
10 % of cases of clinically diagnosed renal angiomyoli-
pomas [8].
Both LAM and angiomyolipoma are closely related to
TSC, and appear to arise from a common source [9].
Furthermore, pulmonary LAM and renal angiomyoli-
poma are also closely related. Renal angiomyolipomas
have been reported to occur in up to 100 % of patients
with TSC-LAM, and in up to 50 % of those with spor-
adic LAM [10–13].
Angiomyolipoma is usually benign, but occasionally
metastasizes distally. Both sporadic pulmonary angio-
myolipoma, and pulmonary metastases originating from
renal angiomyolipoma have been described since 1995
[14]; and in a few cases pulmonary metastasis occurred
years after the nephrectomy for renal angiomyolipoma
[7, 15]. In this case, pulmonary and left renal angiomyo-
lipomas occurred simultaneously 17 years after nephrec-
tomy for right renal angiomyolipoma, and pulmonary
and renal angiomyolipoma histopathology was consist-
ent. Therefore, distal metastases seem the most likely ex-
planation. Regrettably, molecular analysis (e.g. p53 gene
mutation) [16, 17], which could better chatacterize the
homology of renal and pulmonary angiomyolipomas,
was not performed in this patient.
Both pulmonary LAM and renal angiomyolipoma are
rare diseases; and pulmonary angiomyolipoma has been
described in only a few cases. Although the coexistence
of LAM and renal angiomyolipoma is noted in about
50 % of sporadic LAM patients, to the best of our know-
ledge, coexistence of pulmonary LAM and pulmonary
angiomyolipoma has not previously been described.
Genetic analysis suggested that LAM cells could origin-
ate from the smooth muscle cells of renal angiomyoli-
poma, and be transported through the circulation [18].
Therefore, one explanation for the pulmonary coexist-
ence is that the renal angiomyolipoma released tumor
cells to the lung through the blood flow during resection
[15], allowing both metastatic pulmonary angiomyolipo-
mas and LAM to form over a long period of time.
Another explanation is that the patient might already
have had LAM when she underwent nephrectomy since
the patient’s pulmonary evaluation 17 years ago was per-
formed via chest X-ray, and this technique is not suffi-
ciently sensitive to detect an early LAM. In this case
pulmonary angiomyolipomas may have metastasized
from the kidney later. Whichever hypothesis is correct,
LAM and angiomyolipoma appear to be related.
The mTOR inhibitor, sirolimus, stabilizes lung func-
tion and improves some measures of quality of life in pa-
tients with LAM [19, 20]. Sirolimus has been approved
by the US Food and Drug Administration for the treat-
ment of moderate-to-severe pulmonary LAM. Sirolimus
is also efficacious in controlling tumor volume in
Fig. 4 Biopsy specimen of the lung. a and b The cystic lesion’s walls exhibit the accumulation of some spindle-shaped cells which are positive
for HMB45 staining. HE × 10 (a), HMB45 × 60 (b). c and d The nodular lesion is a mixture of adipose tissue, smooth muscle, and small blood
vessels. HE × 10 (c), HE × 60 (d)
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patients with renal angiomyolipomas [21]. Everolimus, a
derivative of sirolimus, also represents a promising treat-
ment for LAM and renal angiomyolipoma [22, 23].
Surgery or embolism is an alternative choice when an
intervention is indicated in patients with renal angio-
myolipomas [24]. Sirolimus therapy was chosen in this
patient in consideration of the coexistence of pulmonary
LAM, pulmonary angiomyolipomas and renal angiomyo-
lipoma. The outcome in this case demonstrated that sir-
olimus was effective not only for renal angiomyolipoma,
but also for metastasized pulmonary angiomyolipomas.
Conclusions
LAM and angiomyolipoma are substantially related,
and may coexist in the lungs in rare cases. Sirolimus
can effectively resolve both renal angiomyolipoma and
metastasized pulmonary angiomyolipomas.
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